Clarus Therapeutics Announces Two Notices of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)
October 26, 2021 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
JATENZO® (testosterone undecanoate) is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical...
Clarus Therapeutics to Present New Real-World Experience Data for JATENZO® (testosterone undecanoate) at the 22nd Annual Fall Scientific Meeting of SMSNA
October 14, 2021 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
JATENZO® (testosterone undecanoate) is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical...
Clarus Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 22, 2021 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing...
Clarus Therapeutics Closes Transaction With Blue Water, Debuts as a Publicly Traded Company to Develop Androgen and Metabolic Therapies
September 09, 2021 12:46 ET
|
Clarus Therapeutics, Inc.; Blue Water Acquisition Corp.
Business combination with Blue Water Acquisition Corp., a special purpose acquisition company, completed on September 9, 2021 Combined company to be renamed Clarus Therapeutics Holdings, Inc. Clarus...
Testosterone Replacement Therapy Market Report 2021-2031: Visiongain Research Inc.
August 03, 2021 11:29 ET
|
Visiongain Ltd
Visiongain has published a new report on Testosterone Replacement Therapy Market Report 2021-2031: Forecasts By Product (Oral, Parenteral, Implants, Gel/Creams, Patches, Buccal Adhesive, and Others),...
Clarus Therapeutics Announces Comprehensive Settlement of Patent Litigation With Lipocine
July 15, 2021 09:00 ET
|
Clarus Therapeutics, Inc.
NORTHBROOK, Ill., July 15, 2021 (GLOBE NEWSWIRE) -- Clarus and Lipocine (NASDAQ: LPCN) agreed to settle all outstanding claims in the patent infringement lawsuit brought against Clarus by Lipocine...
Clarus Announces JATENZO® (Testosterone Undecanoate) Capsules, CIII Now Covered by Express Scripts
December 07, 2020 09:00 ET
|
Clarus Therapeutics, Inc.
JATENZO is the first and only FDA-approved oral testosterone replacement therapy of its kind Coverage effective December 1, 2020 on the Express Scripts National Preferred, Basic and High Performance...
CLARUS THERAPEUTICS ANNOUNCES FINANCING TO SUPPORT THE COMMERCIAL LAUNCH AND AVAILABILITY OF JATENZO® (TESTOSTERONE UNDECANOATE) CAPSULES, CIII FOR THE TREATMENT OF HYPOGONADISM
March 16, 2020 08:00 ET
|
Clarus Therapeutics, Inc.
Financing to speed commercialization of the only FDA-approved oral treatment of its kind for testosterone deficiency1,2 NORTHBROOK, Ill., March 16, 2020 (GLOBE NEWSWIRE) -- Clarus Therapeutics,...
Clarus Therapeutics Announces Commercial Launch and Availability of JATENZO® (testosterone undecanoate) capsules, CIII for the Treatment of Hypogonadism
February 10, 2020 08:00 ET
|
Clarus Therapeutics, Inc.
First and only FDA-approved oral treatment of its kind for testosterone deficiency1,2 NORTHBROOK, Ill., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc. today announced that JATENZO®...
Clarus Therapeutics Expands Executive Team in Preparation for Landmark Launch of JATENZO® (testosterone undecanoate) Capsules CIII
December 11, 2019 14:04 ET
|
Clarus Therapeutics, Inc.
NORTHBROOK, Ill., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc. today announced the appointment of five senior leaders, each of whom bring valuable industry and category experience to...